Humacyte to Participate at Upcoming Investor Conferences in May
Humacyte to Participate at Upcoming Investor Conferences in May
DURHAM, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, Dale Sander, Chief Financial Officer, and B.J. Scheessele, Chief Commercial Officer, will represent Humacyte at the following conferences in May.
北卡羅來納州達勒姆，2024年5月13日（GLOBE NEWSWIRE）——臨床階段的生物技術平台公司Humacyte, Inc.（納斯達克股票代碼：HUMA）今天宣佈，創始人、總裁兼首席執行官勞拉·尼克拉森醫學博士、首席財務官戴爾·桑德和首席B.J. Scheessele 商務官員，將代表Humacyte參加5月的以下會議。
H.C. Wainwright BioConnect Investor Conference at NASDAQ
Format: Fireside Chat and one-on-one investor meetings
Date: Monday, May 20, 2024
Time: 5:00 PM EST
Webcast: https://journey.ct.events/
納斯達克H.C. Wainwright BioConnect投資者會議
形式：爐邊談話和一對一投資者會議
日期：2024 年 5 月 20 日星期一
時間：美國東部標準時間下午 5:00
網絡直播： https://journey.ct.events/
A replay will be available for a limited time following the presentation on the Events & Presentations page within the Investors portion of the Humacyte website.
在Humacyte網站投資者部分的活動和演示頁面上進行演示後，將在有限的時間內提供重播。
Benchmark's 4th Annual Healthcare House Call Investor Conference
Format: One-on-one investor meetings
Date: Tuesday and Wednesday May 21-22, 2024
基準測試的 4第四 年度醫療保健公司電話會議投資者會議
形式：一對一投資者會議
日期：2024 年 5 月 21 日至 22 日星期二和星期三
About Humacyte
關於 Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte's initial opportunity, a portfolio of HAVs, is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, AV access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte's 6mm HAV for AV access in hemodialysis was the first product candidate to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte's 6mm HAV for urgent arterial repair following extremity vascular trauma also has received RMAT designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
Humacyte, Inc.（納斯達克股票代碼：HUMA）正在開發一個顛覆性的生物技術平台，以提供可普遍植入的生物工程人體組織、先進的組織結構和器官系統，旨在改善患者的生活並改變醫學實踐。該公司開發和製造用於治療各種疾病、損傷和慢性病的無細胞組織。Humacyte最初的機會是HAV產品組合，目前正在進行鍼對多種血管應用的後期臨床試驗，包括血管創傷修復、血液透析的AV通路和外周動脈疾病。冠狀動脈旁路移植術、小兒心臟手術、1 型糖尿病治療以及多種新型細胞和組織應用的臨床前開發也在進行中。Humacyte的6mm HAV用於血液透析的AV，是第一款獲得美國食品藥品管理局再生醫學高級療法（RMAT）稱號的候選產品，也獲得了美國食品藥品管理局的快速通道稱號。Humacyte 的 6mm HAV 用於四肢血管創傷後的緊急動脈修復，也獲得了 RMAT 稱號。HAV 被美國國防部長指定爲治療血管創傷的優先項目。欲了解更多信息，請訪問 www.humacyte.com。
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte 投資者聯繫人：
喬伊斯·阿萊爾
LifeSci 顧問有限公司
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
Humacyte 媒體聯繫人：
Rich Luchette
精準策略
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
Source: Humacyte, Inc
資料來源：Humacyte, Inc
譯文內容由第三人軟體翻譯。